Novavax (NVAX) could disappoint investors
Novavax, Inc. (NVAX) currently trades at $17.36 and has fallen by 1.59% today. NVAX went down $0.30 from the previous closing price of $17.64. The high forecast for Novavax, Inc. is $28.00 and the low is $19.00. The company’s market cap is $894.54 million with a 52 week high of $18.25 and a 52 week low of $3.54. NVAX has changed in price by 6.45 per share in the last 12 months. Novavax will have to compete with other COVID-19 vaccines that are currently in development. This includes INO-4800 from Inovio Pharmaceuticals, as well as Moderna’s mRNA-1273, two potential treatments that have already begun testing in humans. Novavax has never had any home runs in the past, ultimately holding a history of disappointing investors.
Novavax, Inc. has a weak EPS of -5.51. This means the company lost $-5.51 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 4 out of 10. We give it this rating based on current information written in this article.
About Novavax, Inc.:
Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis.